Medifast (MED) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month target prices for Medifast's shares. Their MED share price forecasts range from $80.00 to $80.00. On average, they expect the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 3.2% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $115.35 on January 1st, 2023. Since then, MED shares have decreased by 32.8% and is now trading at $77.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) released its earnings results on Monday, August, 7th. The specialty retailer reported $2.77 EPS for the quarter, beating the consensus estimate of $1.44 by $1.33. The specialty retailer earned $296.20 million during the quarter, compared to the consensus estimate of $270.20 million. Medifast had a net margin of 9.68% and a trailing twelve-month return on equity of 89.20%. The business's revenue was down 34.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.87 EPS.

Medifast announced a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be given a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 dividend on an annualized basis and a yield of 8.51%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED.

ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), First Trust SMID Cap Rising Dividend Archievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap Quality ETF (XSHQ), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Royce Quant Small-Cap Quality Value ETF (SQLV) and Global X Health & Wellness ETF (BFIT).

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 8.51%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 54.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, MED will have a dividend payout ratio of 86.73% in the coming year. This indicates that the company may not be able to sustain their current dividend.
Read our dividend analysis for MED.

Medifast updated its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $0.71-$1.32 for the period, compared to the consensus EPS estimate of $1.43. The company issued revenue guidance of $220.00 million-$240.00 million, compared to the consensus revenue estimate of $269.57 million.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.70%), Renaissance Technologies LLC (6.25%), State Street Corp (3.51%), Dimensional Fund Advisors LP (3.10%), Pacer Advisors Inc. (2.22%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $77.54.

Medifast (NYSE:MED) has a market capitalization of $844.41 million and generates $1.60 billion in revenue each year. The specialty retailer earns $143.57 million in net income (profit) each year or $12.12 on an earnings per share basis.

The company employs 874 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.